Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

36.11
+0.05000.14%
Post-market: 36.110.00000.00%19:30 EDT
Volume:699.09K
Turnover:25.30M
Market Cap:3.48B
PE:-18.46
High:36.72
Open:35.94
Low:35.94
Close:36.06
52wk High:42.68
52wk Low:26.05
Shares:96.27M
Float Shares:94.37M
Volume Ratio:1.11
T/O Rate:0.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:2.90
PE(LYR):-28.10

Loading ...

Ideaya Biosciences CEO Yujiro S. Hata Disposes of $986,768 in Common Shares

Reuters
·
Yesterday

IDEAYA Biosciences (IDYA) Stock Looks Priced At A Premium Despite R And D Promotion

Simply Wall St.
·
Oct 01

Press Release: Ideaya Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

Dow Jones
·
Sep 28

Ideaya Biosciences Grants 94,000 Inducement Stock Options at $36.74 a Share

Reuters
·
Sep 25

Ideaya Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 25

Citi Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)

TIPRANKS
·
Sep 11

Analysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Medicus Pharma Ltd (MDCX)

TIPRANKS
·
Sep 09

Ideaya Biosciences Price Target Raised to $57.00/Share from $54.00 by Guggenheim

Dow Jones
·
Sep 09

Ideaya Biosciences doses first patient in OptimUM-11 trial

TIPRANKS
·
Sep 09

Ideaya, Servier Dose First Patient in Phase 3 OptimUM-11 Adjuvant Uveal Melanoma Trial of Darovasertib-Crizotinib Combo

Reuters
·
Sep 09

Ideaya Biosciences and Servier Announce First Patient Dosed in Optimum-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

THOMSON REUTERS
·
Sep 09

Ideaya Biosciences to Host Investor R&D Day in London

Reuters
·
Sep 01

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA)

TIPRANKS
·
Aug 31

Ideaya Targets Year-End 2026 Start for Phase 3 Ide849 Trial in Extensive-Stage Small Cell Lung Cancer

Reuters
·
Aug 31

Ideaya Biosciences, - to Initiate Phase 3 Trial for Ide849 by Year-End 2026 in Es-Sclc

THOMSON REUTERS
·
Aug 31

Ideaya Biosciences Announces Successful FDA Type C Meeting for Ide849, Dll3 Top1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Aug 31

Ideaya Biosciences Grants Inducement Stock Options for 62,800 Shares at USD 41.77 Each

Reuters
·
Aug 28

Ideaya Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 28

Wedbush Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)

TIPRANKS
·
Aug 20

Analysts Conflicted on These Healthcare Names: IDEAYA Biosciences (IDYA) and Definitive Healthcare Corp (DH)

TIPRANKS
·
Aug 20